Featured Articles

31. Drug Discovery And Screening, A Digital Era For RNA-LNP Therapeutics 11/21/2022

    Learn about the key stages of drug discovery and screening as well as how to overcome bottlenecks in screening mRNA-LNPs to rapidly develop genomic medicines.

32. Bringing Allogeneic Cell Therapy To Patient Care 11/1/2022

    Bringing allogeneic cell therapy to patient care will require flexible, closed, and automated solutions to support the treatment options and increasing scale of the industry.

33. Strategies To Overcome Delays In The Development Of Genomic Medicines 10/13/2022

    Learn how optimizing LNPs can help overcome drug-delivery challenges, unlocking potential new genomic medicines in a shorter time.

34. Developing A Scalable RNA-LNP Drug Product For Clinical Translation 9/22/2022

    Accelerate essential process development activities with instrumentation solution allowing for highly reproducible and scalable production of RNA-LNPs.

35. Optimizing Lipid Formulations For Targeted RNA-LNP Applications 9/13/2022

    Learn about the considerations and challenges of using ionizable lipids, including the 5 types of lipids used for RNA delivery.

36. Process Development Considerations For RNA-LNP Therapeutics 9/13/2022

    Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).

37. Key Stages In mRNA-Based Therapeutic Development 9/13/2022

    Learn how planning a product development strategy early on with a technology partner who has deep expertise and technical knowledge of genomic medicines can address uncertainties from the outset.

38. Unlocking The Full Potential Of Genomic Medicine 6/1/2022

    There are two key challenges to realizing the potential of genomic medicines, but potential technological solutions are on the horizon, and we examine each.

39. mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations 6/1/2022

    Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.

40. Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications 4/18/2022

    Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.